Journal of the American Chemical Society · 2024 · 31 citations · 28 references
Life SciencesMolecular BiologyNeuroscienceMolecular NeuroscienceNeurodegenerationStructural BiologyAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseProtein AggregationProtein OligomerizationAggregationAlpha-synuclein AggregationAmyloid Oligomer FormationCell AggregationDisease-related Protein AggregationProtein AggregatesProtein Aggregation InhibitionStructural Biology Of Neurodegenerative Proteins
Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson's disease. However, the development of oligomer-targeting therapeutics is constrained by our limited knowledge of their structure and the molecular determinants driving their conversion to fibrils. Phenol-soluble modulin α3 (PSMα3) is a nanomolar peptide binder of α-synuclein oligomers that inhibits aggregation by blocking oligomer-to-fibril conversion. Here, we investigate the binding of PSMα3 to α-synuclein oligomers to discover the mechanistic basis of this protective activity. We find that PSMα3 selectively targets an α-synuclein N-terminal motif (residues 36-61) that populates a distinct conformation in the mono- and oligomeric states. This α-synuclein region plays a pivotal role in oligomer-to-fibril conversion as its absence renders the central NAC domain insufficient to prompt this structural transition. The hereditary mutation G51D, associated with early onset Parkinson's disease, causes a conformational fluctuation in this region, leading to delayed oligomer-to-fibril conversion and an accumulation of oligomers that are resistant to remodeling by molecular chaperones. Overall, our findings unveil a new targetable region in α-synuclein oligomers, advance our comprehension of oligomer-to-amyloid fibril conversion, and reveal a new facet of α-synuclein pathogenic mutations.
28
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Mihael H. Polymeropoulos, Christian Lavedan, Elisabeth Leroy et al. · Science · 1997 · 8.2K citations
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
In vivo demonstration that α-synuclein oligomers are toxic
Beate Winner, Roberto Jappelli, Samir K. Maji et al. · Proceedings of the National Academy of Sciences · 2011 · 1.5K citations · Full text
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Nunilo Cremades, Samuel I. A. Cohen, Emma Deas et al. · Cell · 2012 · 902 citations · Full text